SEC 13F Intelligence

Duquesne Family Office LLC / ABCL

Duquesne Family Office LLC’s Abcellera Biologics Inc Position

Does Duquesne Family Office LLC own Abcellera Biologics Inc (ABCL)? Not currently — the last reported position was 659.8K shares worth $4M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$4M
Q4 2023
Shares
659.8K
% of Portfolio
+0.11%
Quarters Held
12
position exited

Position History ABCL

Reported value by quarter
Q4 ’20: $27MQ4 ’20Q1 ’21: $22MQ3 ’21: $13MQ3 ’21Q4 ’21: $9MQ1 ’22: $6MQ1 ’22Q2 ’22: $7MQ3 ’22: $7MQ3 ’22Q4 ’22: $7MQ1 ’23: $5MQ1 ’23Q2 ’23: $4MQ3 ’23: $3MQ3 ’23Q4 ’23: $4Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q4 2023659.8K$4M+0.11%
Q3 2023659.8K$3M+0.11%
Q2 2023659.8K$4M+0.15%
Q1 2023659.8K$5M+0.22%
Q4 2022659.8K$7M+0.33%
Q3 2022659.8K$7M+0.37%
Q2 2022659.8K$7M+0.51%
Q1 2022659.8K$6M+0.28%
Q4 2021659.8K$9M+0.34%
Q3 2021659.8K$13M+0.43%
Q1 2021659.8K$22M+0.49%
Q4 2020659.8K$27M+0.72%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Duquesne Family Office LLC’s full portfolio or all institutional holders of ABCL.